Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Military Dermatology: Staffing, Policy, and Duty Restrictions
Description
The talk explains how U.S. military demographics, geography, and health systems shape military dermatology care, then focuses on staffing shortages, policy changes, and duty restrictions relevant to skin disease. It reviews the size and distribution of the force, who military dermatologists treat, and the differences between TRICARE and VA eligibility. The speakers describe the Defense Health Agency’s role, the limited number of active duty dermatologists, and how policy shifts, COVID, the PACT Act, and access concerns have intensified pressure on an already under-resourced system, making civilian partnerships essential. Using a service member with eczema as a case example, the presentation walks through temporary and permanent duty limitations, the importance of documenting functional impact and restrictions, and when specialist input or medical review is needed. It also compares branch-specific approaches to biologics and deployability: the Navy emphasizes operational function and may use employability review, the Air Force uses RILO and waiver processes, and the Army focuses on whether the member can meet baseline operational demands and may require permanent profiling. The talk highlights that biologics and complex dermatologic disease can affect deployment, overseas screening, and family assignments, so clinicians should coordinate early with military providers and understand that treatment decisions can have career and assignment consequences.
View moreConclusions
- Military dermatology is facing a major staffing mismatch, with far too few military dermatologists to care for the large TRICARE population, making civilian partnerships essential for access to specialty care.
- Because military patients’ treatment decisions can affect deployability, duty status, and overseas assignments, dermatologists need to understand branch-specific fitness rules rather than just the skin disease itself.
- Temporary and permanent duty restrictions are handled differently across the Army, Navy, and Air Force, and standardized terminology does not exist across services.
- If a dermatologic condition requires biologic therapy, that does not automatically end a service member’s career, but it usually triggers waiver, review, or medical-board processes.
- In the Navy, biologics and chronic skin disease are judged mainly by whether the member can still perform and deploy, and newer mechanisms like EMPLOY aim to retain functional sailors who are otherwise non-deployable.
- In the Air Force, biologic-requiring disease is more likely to go through I-RILO/A-RILO review, with several common biologics being waiverable on a case-by-case basis.
- In the Army, the standard is strongly tied to rapid deployability and operational readiness, so extensive or poorly controlled disease or medications requiring close monitoring are more likely to be disqualifying.
- Overseas screening is a critical practical issue because injectable, infused, or closely monitored therapies can derail assignments for both service members and their dependents.
- Dermatology care for military patients should be proactive and coordinated with command and primary care so that treatment choices do not become last-minute administrative crises.
- Overall, military dermatology management is as much about preserving mission readiness and family stability as it is about controlling the skin condition itself.
- Army Regulation AR 40-501, DA PAM 611-21, Air Force Instruction AFI 48-133, and MILPERSMAN 1300140.
- DODI 6130.03 retention standards.
- US Air Force Aerospace Medicine Waiver Guide Compendium.
- Army Reg 40-501, “Standards of Medical Fitness.”
- MILPERSMAN 1300-302 and NAVMED 1300/1.